Patient guide · Reviewed May 2026
Complete GLP-1 Monitoring Guide for Australians
If you are taking Ozempic, Wegovy, or Mounjaro in Australia, you were probably given clear instructions on how to inject the medication and manage nausea. You may have received far less guidance on what else to monitor while you are on treatment.
GLP-1 receptor agonists are powerful metabolic medications. They improve blood sugar, reduce weight, and — in many patients — benefit the liver, kidneys, and cardiovascular system. They also change how you eat, how your body handles fluids, and how you relate to food. Monitoring is not about fear; it is about catching problems early and making sure you get the full benefit of treatment.
This guide brings together the six monitoring priorities Australian clinicians increasingly discuss for GLP-1 patients, a practical schedule you can take to your GP, and the exact words to start the conversation.
Published 2026-05-01 · Clinically reviewed 2026-05-31
Patient guide · Reviewed May 2026
Why Monitoring Matters on GLP-1 Medications
Hundreds of thousands of Australians now use semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro). Most were prescribed because they have type 2 diabetes,…
Hundreds of thousands of Australians now use semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro). Most were prescribed because they have type 2 diabetes, obesity, or related metabolic risk factors — the same profile that raises risk for fatty liver disease, kidney disease, cardiovascular events, and thyroid concerns in specific situations.
Telehealth prescribing has made access easier, but many patients report that routine blood tests, liver assessment, and lifestyle support were offered only as optional extras — or not discussed at all. Australian guidelines published in 2025 now recommend structured assessment for patients with metabolic risk factors, particularly liver health. Your monitoring plan should cover more than the injection site.
This article is educational only. It does not replace advice from your GP, endocrinologist, or specialist. Always follow the monitoring plan agreed with your own clinician.
Six Monitoring Priorities
Think of these as six pillars of GLP-1 monitoring. You may not need every test at every visit, but you should know why each area matters.
1. Liver health
Most GLP-1 patients have metabolic risk factors linked to MASLD (metabolic dysfunction-associated steatotic liver disease). The September 2025 MJA consensus recommends FIB-4 assessment and elastography when indeterminate. Semaglutide and tirzepatide often improve liver fat and inflammation — but you need a baseline to know where you started.
GLP-1 liver monitoring — Australian guidelines →
2. Kidney function
GLP-1 medications can protect kidneys in type 2 diabetes, but nausea-related dehydration and rapid weight loss can temporarily affect kidney markers. eGFR and urine albumin (UACR) are the key tests.
3. Thyroid safety
Semaglutide and tirzepatide carry a class warning about thyroid C-cell tumours in rodents. Personal or family history of medullary thyroid cancer or MEN2 is a contraindication. Routine TSH monitoring is recommended for many patients on long-term therapy.
4. Cardiovascular health
Large trials (SELECT, LEADER, SUSTAIN-6) show cardiovascular benefit in high-risk groups. Monitor blood pressure, lipids, and heart rate — especially during dose escalation. Wegovy has PBS listings linked to cardiovascular risk in some patients.
5. Nutrition and lean mass
Appetite suppression can reduce protein intake and muscle mass alongside fat loss. Adequate protein, resistance training, and dietitian input help preserve lean mass and micronutrient status.
6. Mental health and eating behaviour
Changes in food noise, body image, and emotional eating are common. A history of eating disorders requires careful prescribing and psychological support. Plan for what happens if you stop the medication.
Patient guide · Reviewed May 2026
Recommended Monitoring Schedule
Schedules vary by indication, age, and existing conditions. Use this as a discussion starter with your GP — not a rigid protocol.
Schedules vary by indication, age, and existing conditions. Use this as a discussion starter with your GP — not a rigid protocol.
- Before starting (baseline): Full metabolic panel — HbA1c, fasting glucose, lipids, liver function (ALT, AST, GGT, bilirubin), FIB-4 calculation, eGFR, UACR, TSH, full blood count, vitamin B12 if on metformin, blood pressure, weight, waist circumference. Document eating pattern and exercise. Calculate FIB-4; refer for elastography if indeterminate.
- Weeks 4–8 (first dose escalation): Review GI tolerance, hydration, blood pressure. Repeat renal function if dehydrated or unwell. Brief dietitian or GP check on protein intake.
- 3 months: HbA1c (if diabetic), weight, blood pressure, lipids if not done at baseline, liver enzymes, eGFR, UACR. Reassess FIB-4 if liver enzymes changed significantly.
- 6 months: Repeat 3-month panel if stable; otherwise sooner. Psychology check-in if mood, eating behaviour, or body image concerns. Review resistance training and protein targets.
- 12 months and annually: Full monitoring panel as at baseline. TSH annually (or per product information). Liver elastography if FIB-4 remains indeterminate or prior scan showed fibrosis. CDM review if eligible.
- Any time — seek review sooner if: Persistent vomiting or diarrhoea, signs of dehydration, severe abdominal pain, jaundice, neck lump, palpitations, fainting, suicidal thoughts, or rapid unintended weight loss beyond your plan.
What to Say to Your GP
You do not need to memorise medical terminology. A short, clear request is enough:
I'm on [Ozempic / Wegovy / Mounjaro] and want a structured monitoring plan. Can we do baseline bloods — liver panel with FIB-4, kidney function with urine albumin, thyroid, lipids and HbA1c — and schedule follow-up at 3 and 12 months? I'd also like guidance on liver assessment per the 2025 MJA recommendations if I have metabolic risk factors.
If you already have recent bloods from a telehealth provider, bring those results. Your GP can often calculate FIB-4 immediately and avoid duplicate testing.
Patient guide · Reviewed May 2026
Telehealth vs Face-to-Face Monitoring
Many Australians access GLP-1 medications through online clinics. That model works well for prescription renewal and dose titration, but it may not replace…
Many Australians access GLP-1 medications through online clinics. That model works well for prescription renewal and dose titration, but it may not replace annual comprehensive blood work, physical examination, or liver elastography referral.
The strongest monitoring setup combines your prescribing service (for medication continuity) with a regular GP or specialist who holds your full medical record, Chronic Disease Management plan, and referrals to dietitians, psychologists, and hepatologists when needed.
Find a liver elastography clinic near you
Search by suburb or postcode to see accredited clinics offering FibroScan and guided liver elastography across Australia.
Type a suburb or postcode and press Enter to search nearby.
Request a liver scan appointment
Submit your details and we'll route your request to the most appropriate elastography clinic in your area. Most clinics respond within 1–2 business days.
Take action
Request an appointment
Frequently asked questions
Do I need all six types of monitoring if I feel fine?
Feeling well is reassuring but does not rule out silent metabolic disease — especially fatty liver and early kidney changes. A baseline panel establishes your starting point; follow-up frequency depends on your risk factors and what your GP finds.
How often should I have blood tests on Ozempic or Mounjaro?
Most patients benefit from baseline tests before or soon after starting, a check at 3 months during dose escalation, and annual comprehensive monitoring. Your GP may recommend more frequent tests if you have diabetes, kidney disease, abnormal prior results, or significant GI side effects.
Is liver monitoring mandatory for every GLP-1 patient?
Australian guidelines recommend assessment for adults with type 2 diabetes, obesity, or two or more metabolic risk factors — which describes most GLP-1 patients. That starts with FIB-4 from routine bloods, not necessarily a scan. See our liver monitoring guide for the full pathway.
Can my telehealth doctor do all my monitoring?
Some telehealth services offer optional blood panels, but many do not arrange liver elastography, physical examination, or Chronic Disease Management team care. Pairing telehealth prescribing with a local GP is a practical approach most patients use.
What if my GP says monitoring is unnecessary?
Guidelines evolve and not every GP has implemented the 2025 MJA liver recommendations yet. You can share the consensus statement reference (doi: 10.5694/mja2.70008) and ask for a one-off baseline panel. If you remain concerned, seek a second opinion from an endocrinologist or metabolic clinic.
Does stopping GLP-1 mean I can stop monitoring?
Metabolic risk factors often persist after medication stops. Weight regain is common. Your GP may recommend continued annual checks for liver, kidney, and cardiovascular risk even if you discontinue Ozempic, Wegovy, or Mounjaro.
Related reading
Reviewed against: MJA consensus on MAFLD in primary care (September 2025, doi: 10.5694/mja2.70008); TGA product information Ozempic, Wegovy, Mounjaro; SELECT trial (NEJM 2023); LEADER trial (NEJM 2016); FLOW trial kidney outcomes (NEJM 2024); Dietitians Australia position statements on GLP-1 nutrition care.
This article is for educational purposes only. It does not constitute medical advice. Always consult your GP or a specialist about your individual health circumstances.
Next step
Find a liver elastography clinic near you
Search participating clinics across Australia, or talk to your GP about a baseline FIB-4 and elastography.